Mounjaro (tirzepatide injection) is a dual GIP and GLP-1 receptor agonist marketed by Eli Lilly. It is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The approval is supported by the SURPASS clinical trial program, which demonstrated superior A1C reductions compared to semaglutide 1 mg and insulin glargine across five Phase 3 trials.
Coverage is broadly available when prescribed for type 2 diabetes: Mounjaro is on formulary for most commercial plans and Medicare Part D formularies. However, 100% of plans require prior authorization, and coverage is restricted to the FDA-approved diabetes indication. Prescribing Mounjaro for weight management alone is off-label and a common reason for denial. The FDA-approved weight management product from the same molecule is Zepbound (tirzepatide injection).
This guide explains the coverage structure, prior authorization requirements, cost-sharing, and savings programs that access teams and prescribers need to understand.
Who this is for
Pharmacy access teams, managed care liaisons, prior authorization coordinators, and healthcare providers who prescribe Mounjaro and need to understand payer coverage, documentation requirements, and appeal pathways.
FDA-approved indications that drive coverage
Mounjaro has one FDA-approved indication. Coverage hinges on the documented diagnosis matching this indication.
| Indication | Key trial | Approval year |
|---|---|---|
| Glycemic control in type 2 diabetes (adults) | SURPASS program | 2022 |
| Glycemic control in type 2 diabetes (pediatric patients ≥10 years) | SURPASS-PEDS | 2025 (December) |
Prescribing Mounjaro for weight management alone is off-label. Most commercial and all Medicare plans will deny coverage for off-label weight loss. The FDA-approved weight management product from the same molecule is Zepbound.
Key label information
- Mechanism: Dual GIP receptor and GLP-1 receptor agonist
- Dosing: Start 2.5 mg weekly for 4 weeks, titrate by 2.5 mg every 4 weeks as tolerated; max 15 mg weekly
- Boxed warning: Risk of thyroid C-cell tumors; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Formulations: Single-dose prefilled pen (2.5, 5, 7.5, 10, 12.5, 15 mg/0.5 mL) and single-dose vial
Commercial insurance coverage
Formulary placement
Mounjaro is typically placed on specialty tiers (Tier 3 or Tier 4) of commercial formularies. Coverage depends heavily on the documented indication.
Typical commercial cost-sharing:
| Tier | Typical monthly copay | Notes |
|---|---|---|
| Preferred specialty (Tier 3) | $25–$75 | More common on plans with strong GLP-1 coverage |
| Non-preferred specialty (Tier 4) | $100–$250+ | Coinsurance may apply; percentage of list price |
With the Eli Lilly Savings Card, commercially insured patients may pay as little as $25/month for a 3-card maximum (subject to eligibility). Government beneficiaries are excluded.
Prior authorization
100% of plans require prior authorization for Mounjaro. Typical PA criteria include:
- Confirmed diagnosis of type 2 diabetes — documented via ICD-10 code (E11.x), A1C results (typically ≥6.5%), or medical records.
- Step therapy — many plans require documented failure, contraindication, or intolerance of metformin and/or other first-line agents before approving a GLP-1. Some plans require trial of multiple prior therapies.
- Quantity limits — most plans cover one pen per month (four weekly doses).
- No dual therapy — plans will deny concurrent use with other GLP-1 receptor agonists.
Incomplete documentation is the most common reason for PA denial. Access teams should ensure the PA submission includes the diagnosis code, relevant lab results (A1C), medication history, and any contraindication notes for prior therapies.
According to Lilly's Mounjaro Prior Authorization Process Tips guide, the CoverMyMeds platform can streamline PA submissions, with live chat and phone support available at 1-866-452-5017.
Medicare Part D coverage
Medicare Part D covers Mounjaro when prescribed for its FDA-approved diabetes indication. It is not covered for weight loss under current CMS rules.
Key points for Medicare beneficiaries:
- Formulary: Mounjaro is listed on most Part D formularies. UHC's 2026 Complete Drug List includes Mounjaro on formulary.
- Prior authorization: Required by most Part D plans. Documentation requirements mirror commercial PA criteria.
- Cost-sharing: Under the Inflation Reduction Act, the annual out-of-pocket cap for Part D prescriptions is $2,100 in 2026. Beneficiaries may face coinsurance of 25% before reaching the cap.
- IRA negotiation: Mounjaro was not subject to Inflation Reduction Act drug price negotiations taking effect in 2026 or 2027. Ozempic and Wegovy (semaglutide) were selected for negotiation in the second round, with negotiated prices effective 2027.
Medicaid coverage
Medicaid coverage for Mounjaro varies by state:
| State category | Coverage status |
|---|---|
| Covers Mounjaro for T2D with PA | Most states; requires documented diabetes diagnosis |
| Covers with strict PA criteria | Many states require step therapy, documented prior therapy failure |
| Weight loss coverage | Most state Medicaid programs do not cover Mounjaro for weight loss |
Pennsylvania's Medical Assistance program (effective January 1, 2026) requires prior authorization for Mounjaro and documents that step therapy through Ozempic and Wegovy must fail before Mounjaro is approved. This reflects a pattern where many states place Mounjaro as a non-preferred GLP-1 requiring prior authorization and documented failure of preferred agents.
California's Medi-Cal stopped covering GLP-1 medications for weight loss effective January 2026, though Mounjaro remains available for diabetes with prior authorization.
Patients and providers should verify coverage through their state Medicaid formulary or managed care organization's preferred drug list.
Savings and assistance programs
| Program | Monthly cost | Eligibility |
|---|---|---|
| Mounjaro Savings Card (commercial) | As little as $25/month | Commercially insured patients; not available for government beneficiaries |
| LillyDirect Self-Pay Pharmacy | $499/month (all doses) | Uninsured or cash-pay patients ordering through LillyDirect |
| Lilly Cares Patient Assistance Program | Free | Uninsured patients at or below certain income thresholds |
The savings card can be activated by visiting Mounjaro.lilly.com/savings or asking your healthcare provider.
Major payer-specific coverage patterns
Coverage varies significantly by insurer. The following reflects publicly available data as of May 2026.
| Insurer | Typical Mounjaro coverage | Key requirements |
|---|---|---|
| Aetna (commercial) | Covered for T2D | PA required; step therapy common; quantity limits |
| Blue Cross Blue Shield (Anthem) | Commonly covered for diabetes | PA required; may require step therapy; coverage varies by state affiliate |
| Cigna | Available for T2D | PA and quantity limits common; prior lifestyle intervention documentation |
| Humana | Appears on some 2026 formularies | PA and quantity limits; tier placement varies |
| Kaiser Permanente | Covered for T2D within Kaiser formulary | Internal PA process; criteria-based consultation program; lab work and clinical documentation expected |
| UnitedHealthcare / OptumRx | Available for T2D; listed on OptumRx formulary | PA and quantity limits; step therapy may apply; 12-month authorization valid for T2D |
| CVS Caremark | Coverage depends on employer/plan sponsor | PA required; step therapy common |
According to a GoodRx analysis reported by NPR in April 2026, approximately 12 million commercially insured people lost coverage for Wegovy and 12 million lost coverage for Zepbound between 2025 and 2026, as plans tightened GLP-1 coverage for weight management. Mounjaro coverage for diabetes indications has been more stable, but plans are increasingly scrutinizing off-label prescribing.
The Medicare GLP-1 Bridge (July 2026)
On May 7, 2026, CMS announced the Medicare GLP-1 Bridge, a temporary program running from July 1, 2026 through December 31, 2027. The program provides eligible Medicare Part D beneficiaries access to GLP-1 medications approved for weight management — specifically Wegovy, Zepbound (KwikPen), and Foundayo — for a $50 monthly copay. Mounjaro is not an eligible drug under the Bridge because it is not approved for weight management. Mounjaro remains available to Medicare beneficiaries through standard Part D coverage for its FDA-approved diabetes indication.
What to monitor
- IRA price negotiation: Ozempic and Wegovy (semaglutide) were selected for the second round of Medicare drug price negotiations with negotiated prices effective 2027. Mounjaro was not selected but could be in future rounds.
- BALANCE Model: The Medicaid portion of the CMS BALANCE Model is proceeding, with both Novo Nordisk and Lilly agreeing to a $245 net price per 30-day supply for participating drugs. The Medicare Part D portion has been indefinitely delayed (announced April 2026); the Medicare GLP-1 Bridge has been extended through December 31, 2027 to fill the gap.
- Medicare GLP-1 Bridge rollout: Monitor CMS guidance on the July 2026 launch, eligible populations, and participating Part D plans.
- Formulary shifts: Some commercial plans are tightening GLP-1 PA criteria or moving GLP-1s to higher tiers for 2026. Monitor plan formulary updates during open enrollment.
- Pediatric indication: The December 2025 FDA approval of Mounjaro for pediatric patients ≥10 years with T2D may open new coverage pathways for this population.
Sources
- FDA, Mounjaro prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
- FDA, Mounjaro approval for pediatric T2D (sNDA 215866/S-039): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215866Orig1s039ltr.pdf
- Eli Lilly, Mounjaro Prior Authorization Process Tips: https://mounjaro.lilly.com/assets/pdf/prior-authorization-guide.pdf
- Eli Lilly, SURPASS-2 trial results (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- KFF, BALANCE Model for GLP-1s in Medicare and Medicaid: https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
- CMS, Medicare GLP-1 Bridge eligible drugs: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- Pennsylvania DHS, Medical Assistance Bulletin (PA criteria for GLP-1s, January 2026): https://www.pa.gov/content/dam/copapwp-pagov/en/dhs/documents/docs/publications/documents/forms-and-pubs-omap/mab2025112403.pdf
- Kaiser Permanente Northwest, Mounjaro coverage criteria: https://healthy.kaiserpermanente.org/content/dam/kporg/final/documents/formularies/nw/kp-mounjaro-nw-en.pdf
- UHC, 2026 Complete Drug List (formulary): https://www.uhc.com/medicare/alphadog/AANC26HM0348742_000
- Drugs.com, Is Mounjaro covered by insurance or Medicare: https://www.drugs.com/medical-answers/mounjaro-covered-insurance-medicare-3571888/
